

CITATION REPORT

List of articles citing

Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation

DOI: 10.1161/strokeaha.118.021387
Stroke, 2018, 49, 2421-2429.

Source: <https://exaly.com/paper-pdf/70748560/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
37	2018 Korean Guideline of Atrial Fibrillation Management. <i>Korean Circulation Journal</i> , 2018 , 48, 1033-1080.	4.2	68
36	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 187-209	4.1	15
35	Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. <i>Chest</i> , 2019 , 156, 529-543	5.3	62
34	Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review. <i>PLoS ONE</i> , 2019 , 14, e0213379	3.7	10
33	Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 701-710	3.9	16
32	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13285	2.9	7
31	Understanding family involvement in body donation in Hong Kong: A qualitative study of registered donors and bereaved family members. <i>Health and Social Care in the Community</i> , 2020 , 28, 270-278	2.6	8
30	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020 , 22, I1-I12	1.5	2
29	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , 2020 , 10, e040449	3	5
28	Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. <i>CJC Open</i> , 2020 , 2, 641-651	2	3
27	Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2467-2486	6.4	52
26	Thrombus in the left atrial appendage in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants in clinical practice-A multicenter registry. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 2005-2012	2.7	1
25	Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e014177	6	30
24	Nonvitamin K oral anticoagulants in cardiac surgery: What cardiothoracic surgeons need to know 2.0. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 ,	1.5	2
23	The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e25216	1.8	1
22	Renal Disease and Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2021 , 13, 95-112	1.4	2
21	Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2021 , 78, 678-689.e1	7.4	1

20	Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency. <i>Thrombosis Journal</i> , 2021 , 19, 50	5.6	2
19	Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	2
18	Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. <i>Egyptian Heart Journal</i> , 2021 , 73, 70	1.3	3
17	The PAR-1 antagonist vorapaxar ameliorates kidney injury and tubulointerstitial fibrosis. <i>Clinical Science</i> , 2020 , 134, 2873-2891	6.5	9
16	Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. <i>Cardiology in Review</i> , 2021 , 29, 120-130	3.2	2
15	The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. <i>PLoS ONE</i> , 2020 , 15, e0242922	3.7	9
14	Cardiovascular Research Using the Korean National Health Information Database. <i>Korean Circulation Journal</i> , 2020 , 50, 754-772	2.2	54
13	Novel Oral Anticoagulants [Do Real-world Data Support our Expectations?]. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2019 , 5, 48	0.3	
12	Dose Selection of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Non-Valvular Atrial Fibrillation. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 2020 , 2, 1	0.2	
11	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.. <i>European Heart Journal Supplements</i> , 2022 , 24, A11-A18	1.5	
10	Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis.. <i>Cardiology Research and Practice</i> , 2022 , 2022, 4713826	1.9	
9	Thromboembolic disease treatment during cancer therapy. 2023 , 162-174		
8	Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 9 ,	5.4	0
7	Stroke Prevention in Atrial Fibrillation. 2022 ,		
6	Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation.		0
5	Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis. 9 ,		0
4	The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function [A systematic review. 2022 , 107123		0
3	Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. 2022 , 17, e0278693		0

- 2 Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis. **2023**, 10, 13 ○
- 1 Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data. **2023**, 18, e0279297 ○